A total of 112 AIDS and no AIDS cryptococcosis patients admitted at Emílio Ribas Hospital - São Paulo, Brazil, were treated with amphotericin B (AMB) or amphotericin B and 5 fluorcytosine (5FC). Age, race, predisposing and epidemiological factors, respiratory symptons were evaluated. Goodman tests applied in three patients groups (I, II and III) with associate or unique therapy revealed: 1. prognostic factors: leukocytes ang glucose showed similar response in groups I, II and 111 and protein spinal fluid after l.Sg/AMB; 2. India ink tests and Cryptococcus culture were often positive until l.Og/AMB; 3. significant hypokalemia during monotherapy. Hypo and hyperkalemia had similar data in associate therapy; 4. significant difference in adverse reactions often appeared above 0.7g AMB/250g 5FC; 5. early and late death were common in group 111 (unique) and group I (no AIDS) and III (2.5 to 4. Og) respectively; 6. similar remission and deaths were verified in AIDS/ cryptococosis. Conclusions: adverse reactions were observed above 0.75g/AMBplus 250g 5FC. Association was important in initial therapy and AMB maintenance permitted late relapses.
Neurocryptococcosis; AIDS and no AIDS; Therapy